Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral therapy
Biotech
Gilead blames low infection rates for ending 2 RSV trials
Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.
James Waldron
Jun 27, 2025 4:09am
Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial
Dec 9, 2024 9:35am
Enanta makes the case for COVID-19 antiviral's mixed data
May 9, 2023 9:47am
Virios fails in fibromyalgia but claims efficacy in omicron era
Sep 19, 2022 9:00am
Pfizer, in a rare COVID-19 setback, dumps Paxlovid's IV sibling
Feb 8, 2022 8:20am
Novartis splashes cash on COVID-19 antiviral, plans FDA filing
Jan 10, 2022 4:48am
